SAN FRANCISCO — The team behind Rezo Therapeutics, a new biotech co-founded by a group of University of California, San Francisco, scientists and industry veterans George Scangos and Norbert Bischofberger, was weighing if, and how, to finally come out of stealth mode after nearly five years of work.
It was September, and Rezo’s board was meeting for the first time after closing the company’s Series A round. Then, Scangos made a serendipitous suggestion: What about the J.P. Morgan Healthcare Conference?
“We all thought, if we get a spot at JPM, we’ve got to take it,” CEO Nevan Krogan said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect